Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/10/2026

1. META
2. SPY
3. USO
4. MU
5. MSFT
6. COST
7. IONS
8. CG
9. AVAV
10. SKHY

Go back to Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
(NASDAQ: LYEL) Delayed: 15.21 -0.19 (1.23%)
Previous Close $15.40    52 Week High $ 
Open $15.15    52 Week Low $ 
Day High $16.07    P/E N/A 
Day Low $14.83    EPS $ 
Volume 137,360